Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Xiaomeng Chong, Lixin Wang, Changqin Hu & Langchong He. (2022) Quality control and consistency evaluation of ceftriaxone sodium for injection. Journal of Chemotherapy 0:0, pages 1-14.
Read now
Read now
Phong Thi Nam Nguyen, Nho Van Le, Hanh Minh Nguyen Dinh, Bao Quoc Phan Nguyen & Thi Van Anh Nguyen. (2022) Lung penetration and pneumococcal target binding of antibiotics in lower respiratory tract infection. Current Medical Research and Opinion 38:12, pages 2085-2095.
Read now
Read now
Stephan Schmidt, Edgar Schuck, Vipul Kumar, Olaf Burkhardt & Hartmut Derendorf. (2007) Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents – minimum inhibitory concentration versus time-kill curves. Expert Opinion on Drug Discovery 2:6, pages 849-860.
Read now
Read now
I. Friedland, L.A. Mixson, A. Majumdar, M. Motyl & G.L. Woods. (2002)
In vitro Activity of Ertapenem against Common Clinical Isolates in Relation to Human Pharmacokinetics. Journal of Chemotherapy 14:5, pages 483-491.
Read now
Read now
Articles from other publishers (51)
Fawaz Alasmari, Mohammed S. Alasmari, Hussa Mubarak Muwainea, Hatun A. Alomar, Abdullah F. Alasmari, Sary Alsanea, Aws Alshamsan, Muhammad F. Rasool & Faleh Alqahtani. (2023) Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing. Frontiers in Pharmacology 14.
Crossref
Crossref
Samuel Raemy, Carlo Casanova, Rossella Baldan, Erin Barreto, Aaron J. Tande, Andrea Endimiani, Stephen L. Leib, Urs Fischer & Parham Sendi. (2023) Penicillin-Susceptible Streptococcus pneumoniae Meningitis in Adults: Does the Ceftriaxone Dosing Matter?. Antibiotics 12:5, pages 878.
Crossref
Crossref
Tim M J Ewoldt, Soma Bahmany, Alan Abdulla, Anouk E Muller, Henrik Endeman & Birgit C P Koch. (2023) Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions?. Journal of Antimicrobial Chemotherapy 78:4, pages 1059-1065.
Crossref
Crossref
Maria Sanz-Codina, Sebastian G Wicha, Beatrix Wulkersdorfer, Valentin Al Jalali, Wisse Van Os, Matthias G Vossen, Martin Bauer, Edith Lackner, Christoph Dorn & Markus Zeitlinger. (2022) Comparison of ultrafiltration and microdialysis for ceftriaxone protein-binding determination. Journal of Antimicrobial Chemotherapy.
Crossref
Crossref
Hifza Ahmed, Felix Bergmann & Markus Zeitlinger. (2022) Protein Binding in Translational Antimicrobial Development-Focus on Interspecies Differences. Antibiotics 11:7, pages 923.
Crossref
Crossref
Chikao Onogi, Akinori Osada, Kentaro Imai, Tetsushi Mimura, Yosuke Saka, Yoshimichi Urahama, Hideto Oishi & Tomohiko Naruse. (2022) Two cases of ceftriaxone‐induced encephalopathy treated by hemoperfusion in hemodialysis patients. Hemodialysis International 26:3.
Crossref
Crossref
C. Jongmans, A. E. Muller, P. Van Den Broek, B. De Melo Cruz De Almeida, C. Van Den Berg, J. Van Oldenrijk, P. K. Bos & B. C. P. Koch. (2022) An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review. Frontiers in Pharmacology 13.
Crossref
Crossref
Robert Hertzsch & Angelika Richter. (2022) Systematic Review of the Pharmacological Evidence for the Selection of Antimicrobials in Bacterial Infections of the Central Nervous System in Dogs and Cats. Frontiers in Veterinary Science 8.
Crossref
Crossref
Sonya Tang Girdwood, Min Dong, Peter Tang, Erin Stoneman, Rhonda Jones, Toni Yunger, Austin Ostermeier, Calise Curry, Melissa Forton, Traci Hail, Randi Mullaney, Patrick Lahni, Nieko Punt, Jennifer Kaplan & Alexander A. Vinks. (2022) Population Pharmacokinetic Modeling of Total and Free Ceftriaxone in Critically Ill Children and Young Adults and Monte Carlo Simulations Support Twice Daily Dosing for Target Attainment. Antimicrobial Agents and Chemotherapy 66:1.
Crossref
Crossref
Jayesh A. Dhanani, Benjamin Ahern, Liad Lupinsky, Karen Jackson, Steven C. Wallis, Mohd H. Abdul-Aziz, Jeffrey Lipman & Jason A. Roberts. (2020) Comparative Plasma Pharmacokinetics of Ceftriaxone and Ertapenem in Normoalbuminemia, Hypoalbuminemia, and Albumin Replacement in a Sheep Model. Antimicrobial Agents and Chemotherapy 64:7.
Crossref
Crossref
E Leegwater, B V C Kraaijenbrink, D J A R Moes, I M Purmer & E B Wilms. (2020) Population pharmacokinetics of ceftriaxone administered as continuous or intermittent infusion in critically ill patients. Journal of Antimicrobial Chemotherapy 75:6, pages 1554-1558.
Crossref
Crossref
Andrew Cristinacce, James G. Wright, Gregory G. Stone, Jennifer Hammond, Lynn McFadyen & Susan Raber. (2019) A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators. Infectious Diseases and Therapy 8:2, pages 185-198.
Crossref
Crossref
Roipim Mapongpeng, Weerapong Laovechprasit, Amnart Poapolathep, Mario Giorgi, Chalatip Junchompoo, Chainarong Sakulthaew, Usuma Jermnak, Wanida Passadurak & Saranya Poapolathep. (2019)
Pharmacokinetics of ceftriaxone in Green sea turtles (
Chelonia mydas
) following intravenous and intramuscular administration at two dosages
. Journal of Veterinary Pharmacology and Therapeutics 42:1, pages 104-110.
Crossref
Crossref
Sarah Allegra, Chiara Simona Cardellino, Giovanna Fatiguso, Jessica Cusato, Amedeo De Nicolò, Valeria Avataneo, Stefano Bonora, Antonio D'Avolio, Giovanni Di Perri & Andrea Calcagno. (2018)
Effect of
ABCC2
and
ABCG2
Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations
. The Journal of Clinical Pharmacology 58:12, pages 1550-1556.
Crossref
Crossref
Roger L. Nation, Ursula Theuretzbacher & Brian T. Tsuji. (2018) Concentration-dependent plasma protein binding: Expect the unexpected. European Journal of Pharmaceutical Sciences 122, pages 341-346.
Crossref
Crossref
Larry H. Danziger & Karolyn S. Horn. 2018. Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions. Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions
1
56
.
Ayman F. El‐Kattan. 2017. Oral Bioavailability Assessment. Oral Bioavailability Assessment
1
34
.
John F. Kokai-Kun, J. Andrew Bristol, John Setser & Michael Schlosser. (2015) Nonclinical Safety Assessment of SYN-004. International Journal of Toxicology 35:3, pages 309-316.
Crossref
Crossref
Jatinder Kaur Mukker, Ravi Shankar Prasad Singh & Hartmut Derendorf. 2016. Antibiotic Pharmacodynamics. Antibiotic Pharmacodynamics
109
125
.
Michael Schleibinger, Cathérine L. Steinbach, Christoph Töpper, Alexander Kratzer, Uwe Liebchen, Frieder Kees, Bernd Salzberger & Martin G. Kees. (2015) Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. British Journal of Clinical Pharmacology 80:3, pages 525-533.
Crossref
Crossref
Gregory S. Basarab, Gunther H. Kern, John McNulty, John P. Mueller, Kenneth Lawrence, Karthick Vishwanathan, Richard A. Alm, Kevin Barvian, Peter Doig, Vincent Galullo, Humphrey Gardner, Madhusudhan Gowravaram, Michael Huband, Amy Kimzey, Marshall Morningstar, Amy Kutschke, Sushmita D. Lahiri, Manos Perros, Renu Singh, Virna J. A. Schuck, Ruben Tommasi, Grant Walkup & Joseph V. Newman. (2015) Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Scientific Reports 5:1.
Crossref
Crossref
Yanli Zhao, Merit E. Cudkowicz, Jeremy M. Shefner§, Lisa Krivickas, William S. David, Francine Vriesendorp, Alan Pestronk, James B. Caress, Jonathan Katz, Ericka Simpson, Jeffrey Rosenfeld, Robert Pascuzzi, Jonathan Glass, Kourosh Rezania, Jerold S. Harmatz, David Schoenfeld & David J. Greenblatt. (2014) Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis. The Journal of Clinical Pharmacology 54:10, pages 1180-1187.
Crossref
Crossref
Eric Dailly, Marie-Clémence Verdier, Guillaume Deslandes, Régis Bouquié, Olivier Tribut & Danièle Bentué-Ferrer. (2012) Niveau de preuve du suivi thérapeutique pharmacologique de la ceftriaxone. Therapies 67:2, pages 145-149.
Crossref
Crossref
Marilyn E. Morris, Xinning Yang, Yash A. Gandhi, Suraj G. Bhansali & Lisa J. Benincosa. (2012) Interspecies scaling: prediction of human biliary clearance and comparison with QSPKR. Biopharmaceutics & Drug Disposition 33:1, pages 1-14.
Crossref
Crossref
Denis Garot, Renaud Respaud, Philippe Lanotte, Nicolas Simon, Emmanuelle Mercier, Stephan Ehrmann, Dominique Perrotin, Pierre-François Dequin & Chantal Le Guellec. (2011) Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. British Journal of Clinical Pharmacology 72:5, pages 758-767.
Crossref
Crossref
Hans-Rudolf Schmutz, Pascal Detampel, Theo Bühler, André Büttler, Benjamin Gygax & Jörg Huwyler. (2011) In Vitro Assessment of the Formation of Ceftriaxone–Calcium Precipitates in Human Plasma. Journal of Pharmaceutical Sciences 100:6, pages 2300-2310.
Crossref
Crossref
Francis F. Arhin, Adam Belley, Geoffrey McKay, Sylvain Beaulieu, Ingrid Sarmiento, Thomas R. ParrJr.Jr. & Gregory Moeck. (2010) Assessment of Oritavancin Serum Protein Binding across Species. Antimicrobial Agents and Chemotherapy 54:8, pages 3481-3483.
Crossref
Crossref
C. Adembri, L. Vitali, V. Selmi, S. Arrigucci & A. R. De Gaudio. (2010) Experimental sepsis is associated with significant changes in antimicrobial pharmacokinetics. European Journal of Anaesthesiology 27, pages 172-173.
Crossref
Crossref
Shayne Cox GadAlexander V. Lyubimov & Ihor Bekersky. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia.
J.M. Stevenson, J.H. Patel, M.D. Churchwell, A.M. Vilay, D.D. Depestel, F. Sörgel, M. Kinzig, V. Jakob & B.A. Mueller. (2018) Ertapenem clearance during modeled continuous renal replacement therapy. The International Journal of Artificial Organs 31:12, pages 1027-1034.
Crossref
Crossref
D. M. BOOTHE & J. PERKINS. (2008) Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs. Journal of Veterinary Pharmacology and Therapeutics 31:6, pages 544-553.
Crossref
Crossref
Stephan Schmidt, Katharina Röck, Martina Sahre, Olaf Burkhardt, Martin Brunner, Maximilian T. Lobmeyer & Hartmut Derendorf. (2008) Effect of Protein Binding on the Pharmacological Activity of Highly Bound Antibiotics. Antimicrobial Agents and Chemotherapy 52:11, pages 3994-4000.
Crossref
Crossref
A. Goudah. (2008) Pharmacokinetic parameters of ceftriaxone after single intravenous and intramuscular administration in camels (Camelus Dromedarius). Research in Veterinary Science 84:3, pages 483-489.
Crossref
Crossref
G. A. ALBARELLOS, V. E. KREIL & M. F. LANDONI. (2007) Pharmacokinetics of ceftriaxone after intravenous, intramuscular and subcutaneous administration to domestic cats. Journal of Veterinary Pharmacology and Therapeutics 30:4, pages 345-352.
Crossref
Crossref
Akira Ohno, Yoshikazu Ishii, Keizo Yamaguchi & Intetsu Kobayashi. (2007) Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and β-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia. Journal of Infection and Chemotherapy 13:5, pages 296-301.
Crossref
Crossref
A. GOUDAH, H. C. SHIN, J. H. SHIM & A. M. ABD EL-ATY. (2006) Characterization of the relationship between serum and milk residue disposition of ceftriaxone in lactating ewes. Journal of Veterinary Pharmacology and Therapeutics 29:4, pages 307-312.
Crossref
Crossref
M. M. Ismail. (2005) Pharmacokinetics, Urinary and Mammary Excretion of Ceftriaxone in Lactating Goats. Journal of Veterinary Medicine Series A 52:7, pages 354-358.
Crossref
Crossref
C. Thallinger & C. Joukhadar. 2005. Anaesthesia, Pain, Intensive Care and Emergency Medicine — A.P.I.C.E.. Anaesthesia, Pain, Intensive Care and Emergency Medicine — A.P.I.C.E.
167
175
.
A. K. Majumdar, D. G. Musson, K. L. Birk, C. J. Kitchen, S. Holland, J. McCrea, G. Mistry, M. Hesney, L. Xi, S. X. Li, R. Haesen, R. A. Blum, R. L. Lins, H. Greenberg, S. Waldman, P. Deutsch & J. D. Rogers. (2002) Pharmacokinetics of Ertapenem in Healthy Young Volunteers. Antimicrobial Agents and Chemotherapy 46:11, pages 3506-3511.
Crossref
Crossref
Paul Metz, Sue J. Kohlhepp & D.N. Gilbert. (2002) Study of different off-line sample processing procedures and the measurement of antibiotic and antiviral levels in human serum by high-performance liquid chromatography. Journal of Chromatography B 773:2, pages 159-166.
Crossref
Crossref
Martha J. Gentry-Nielsen, Keith M. Olsen & Laurel C. Preheim. (2002) Pharmacodynamic Activity and Efficacy of Linezolid in a Rat Model of Pneumococcal Pneumonia. Antimicrobial Agents and Chemotherapy 46:5, pages 1345-1351.
Crossref
Crossref
H Elkhaili, P Zachary, L Linger, C Gallion, H Monteil & F Jehl. (2001) Bactericidal activity of bound ceftriaxone against Streptococcus pneumoniae. Médecine et Maladies Infectieuses 31:6, pages 410-416.
Crossref
Crossref
H Elkhaili, P Zachary, L Linger, C Gallion, H Monteil & F Jehl. (2001) Activité bactéricide de la fraction liée de la ceftriaxone sur Streptococcus pneumoniae. Médecine et Maladies Infectieuses 31:6, pages 403-409.
Crossref
Crossref
Sue J. Kohlhepp, David N. Gilbert & James E. Leggett. (1998) Influence of Assay Methodology on the Measurement of Free Serum Ceftriaxone Concentrations. Antimicrobial Agents and Chemotherapy 42:9, pages 2259-2261.
Crossref
Crossref
Andreas Kovar, Teresa Dalla Costa & Hartmut Derendorf. (1997) Comparison of Plasma and Free Tissue Levels of Ceftriaxone in Rats by Microdialysis. Journal of Pharmaceutical Sciences 86:1, pages 52-56.
Crossref
Crossref
N. C. RINGGER, E. G. PEARSON, R. GRONWALL & S. J. KOHLEPP. (2010) Pharmacokinetics of ceftriaxone in healthy horses. Equine Veterinary Journal 28:6, pages 476-479.
Crossref
Crossref
H. Elkhaïli, D. Leveque, J.D. Peter, J. Salmon, Y. Salmon, G. Kaltenbach, A. Cavalier, L. Linger, D. Pompei, H. Monteil & F. Jehl. (1996) Validation du modèle de microporc Yucatan pour les études pharmacocinétiques du ceftriaxone, céfépime, cefpirome et méropénème. Médecine et Maladies Infectieuses 26, pages 599-604.
Crossref
Crossref
José-Esteban Peris, María Pascual-Arce, Luis Granero, Jesús Chesa-Jiménez & Mercedes Almela. (1995) Renal and nonrenal clearances of ceftriaxone at the steady-state and its relation to plasma protein binding. European Journal of Pharmaceutical Sciences 3:3, pages 133-138.
Crossref
Crossref
Philippe Bourget, Valérie Quinquis-Desmaris & Hervé Fernandez. (2016) Ceftriaxone Distribution and Protein Binding between Maternal Blood and Milk Postpartum. Annals of Pharmacotherapy 27:3, pages 294-297.
Crossref
Crossref
P BourgetH FernandezV QuinquisC Delouis. (1993) Pharmacokinetics and protein binding of ceftriaxone during pregnancy. Antimicrobial Agents and Chemotherapy 37:1, pages 54-59.
Crossref
Crossref
Ann Toth, Hisham Y. Abdallah, Raman Venkataramanan, Lewis Teperman, Glen Halsf, Mordechai Rabinovitch, Gilbert J. Burckart & Thomas E. Starzl. (1991) Pharmacokinetics of Ceftriaxone in Liver-Transplant Recipients. The Journal of Clinical Pharmacology 31:8, pages 722-728.
Crossref
Crossref